> ## Content Index
> Fetch the complete content index at: https://acentricresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AI × Biotechnology: Intersection Brief – November 2026
- URL: https://acentricresearch.com/research/ai-biotechnology-brief-2026-11/
- Published: 2026-11-20T16:15:21.000Z
- Updated: 2026-11-20T20:25:11.000Z
- Author: Kevin Meyer
- Tags: ai-biotechnology, intersection-brief

> Acentric Research is produced with AI tools under human review. It is affiliated with Acentric Capital, a private investment group whose members may hold positions in companies discussed. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in [AI × Biotechnology in the Landscape Report](https://acentricresearch.com/research/landscape-2026-11/#ai-biotechnology).

### Overview

Artificial intelligence (AI) and biotechnology meet wherever software that learns from data changes what a doctor, a patient or a drug developer can do. Some of this is already in products. The U.S. Food and Drug Administration (FDA) states that it has authorized over 1,600 AI-enabled medical devices for marketing as of September 2026\. \[1\] Some is in early clinical studies, such as implants that decode brain signals. Some is aimed at the cost and length of drug development, in clinical trials and in drug discovery.

What stands out is how unevenly the evidence is spread. Authorized devices have an official public list. Elsewhere, much of what is public is what companies and agencies say about their own plans. The dated sources opened run from September 2022 to December 2025, plus the FDA list, company pages and the Acentric Research report read in November 2026; later developments were not searched.

### Current state

**What AI does for biotechnology.** In devices, software reads images and body signals and reports what it finds. FDA’s own examples of listed devices include an imaging system that gives diagnostic information for skin cancer, software that uses deep learning to sharpen images, AI systems that detect diabetic retinopathy from retinal images, and a smart sensor that estimates the probability of a heart attack. \[1\] In implanted brain-computer interfaces, AI turns recorded brain activity into something a person can use. Paradromics, a developer, says an external computer with advanced AI processes data from its implant to support translating brain activity into intended speech or computer control. \[2\] In drug development, the U.S. Advanced Research Projects Agency for Health (ARPA-H) describes a program that seeks adaptive platform trials combining predictive computational models, shared infrastructure and real-time analysis. \[3\]

**What biotechnology does for AI.** Biology and medicine supply the signals and the data that the software learns from, and the clinical settings where it is tested. Paradromics describes microelectrodes that capture activity from individual neurons. \[2\] Unlearn, a company that builds AI-generated “digital twins” (forecasts of one participant’s clinical outcomes) for clinical trials, announced access to data from the CHDI Foundation to advance its Huntington’s disease modeling. \[4\] FDA supplies a defined route to market for devices, and publishes guidance on AI-enabled device software. \[1\]

**Who is working on it.** Brain-computer interface developers include Paradromics, Synchron and Neuralink, each describing its work in clinical studies or trials in its own words; this list is not complete. \[2\]\[5\]\[6\] For clinical trials, ARPA-H runs the SURPASS program, \[3\] and Unlearn works with drug developers on trial design and analysis. \[4\]

**Three Junctions, and a fourth area with its own report.**

- **AI-enabled diagnostic and imaging devices** are software inside devices that help find disease, many of them already authorized by FDA. See the [Junction Brief](https://acentricresearch.com/research/ai-diagnostic-imaging-devices-brief-2026-11/).
- **AI physiological monitoring and neural interfaces** covers software that interprets continuous body signals in wearable and implanted devices, including brain-computer interfaces now in early studies in people. See the [Junction Brief](https://acentricresearch.com/research/ai-physiological-monitoring-neural-interfaces-brief-2026-11/).
- **AI in clinical trials** covers AI used to design trials, match patients and run them. A federal funding call and one European regulatory qualification exist, and measured evidence of faster or more successful trials was not found. See the [Junction Brief](https://acentricresearch.com/research/ai-clinical-trials-brief-2026-11/).
- **AI × Drug Discovery** has its own full report. It found that FDA approved lirafugratinib on 2026-09-23\. The molecule comes from Relay Therapeutics, which names machine learning as one part of its platform but not as the designer of the molecule, and is licensed to Elevar Therapeutics. Of 32 candidates tied to AI and in trials by the end of 2023, 13 have been stopped, a share that depends on the report’s counting rules. The gain companies claim is faster discovery of a drug candidate; the report found trials of these candidates were not shorter overall and no early-trial advantage over the industry baseline. \[7\] See the [Junction Report](https://acentricresearch.com/research/ai-drug-discovery-2026-11/).

One area was left out: health-care administration and language models in medicine, where AI is a general tool and removing it leaves the medical technology unchanged. Other parts of the pair, such as genomics and longevity, were not examined. \[8\]

### Opportunities

Rules are still being written. FDA lists a final guidance on change control plans for AI-enabled device software and a draft guidance on lifecycle management. \[1\] The European Medicines Agency (EMA) qualified Unlearn’s PROCOVA method for Phase 2 and 3 trials with continuous outcomes in 2022, according to a trade publication, which describes it as the first regulatory backing of a machine-learning method for reducing sample sizes in pivotal trials. \[9\] ARPA-H has an open solicitation aimed at trials of under four years. \[3\] Results from the implant studies would move claims from company pages to registries and journals; Synchron says its implant is being assessed in clinical trials. \[5\]

### Challenges

- **Regulation.** Devices go through FDA premarket pathways, and FDA lists its lifecycle guidance as a draft. \[1\] The brain-computer interfaces described here are investigational: Synchron states its system is not approved for commercial use in any geography. \[5\]
- **Evidence of benefit.** FDA’s list records authorizations. \[1\] The sources opened for this Brief do not report patient outcomes. For drug discovery, the full report found no early-trial advantage that could be told apart from the industry baseline. \[7\] For trials, no measured result was found in the sources opened.
- **Engineering.** Whether implanted systems stay stable over years in patients is what the studies are designed to examine. \[2\]
- **Capital and scale-up.** Two early financings of trial-related tools were found, of $4.7 million and $13 million; financing was not searched systematically. \[10\]\[11\]

### Data sources

- **FDA’s list of AI-enabled devices** and the FDA device databases for 510(k) notifications, De Novo requests and premarket approvals (PMA). \[12\]
- **ClinicalTrials.gov** for registered trials and implant studies. AI use in a trial is not a coded field, so it can only be found by text search. \[13\]
- **SEC EDGAR** for company filings, including prospectuses and annual reports. \[14\]
- **ARPA-H program pages** and **NIH RePORTER**, for federal funding calls and grants. \[15\]\[16\]
- **EMA qualification opinions** for methods accepted for use in medicine development. \[17\] A coded list of AI methods in trials does not exist in the sources opened.

### Changelog

- 2026-11-18: First published.

### Sources

1. US Food and Drug Administration, “Artificial Intelligence-Enabled Medical Devices”. [fda.gov](https://www.fda.gov/medical-devices/digital-health-center-excellence/artificial-intelligence-enabled-medical-devices?ref=acentricresearch.com) (accessed 2026-11-18)
2. Paradromics, Inc., “Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus® Brain-Computer Interface”, 2025-11-20 (company press release). [paradromics.com](https://www.paradromics.com/news/paradromics-receives-fda-approval-for-the-connect-one-clinical-study-with-the-connexus-brain-computer-interface?ref=acentricresearch.com) (accessed 2026-11-18)
3. ARPA-H, “SURPASS: Simulation-augmented, Real-time Platform Adaptive Seamless Trials” (program page). [arpa-h.gov](https://arpa-h.gov/explore-funding/programs/surpass?ref=acentricresearch.com) (accessed 2026-11-18)
4. Unlearn.ai, Inc., company home page (company claims). [unlearn.ai](https://www.unlearn.ai/?ref=acentricresearch.com) (accessed 2026-11-18)
5. Synchron, Inc., company home page (company claims). [synchron.com](https://synchron.com/?ref=acentricresearch.com) (accessed 2026-11-18)
6. Neuralink, company home page (company claims). [neuralink.com](https://neuralink.com/?ref=acentricresearch.com) (accessed 2026-11-18)
7. Acentric Research, “AI × Drug Discovery: The Intersection Ecosystem – November 2026”, 2026-11-17\. [acentricresearch.com](https://acentricresearch.com/research/ai-drug-discovery-2026-11/) (accessed 2026-11-18)
8. Acentric Research, “Landscape Report, November 2026”, exclusions and limitations. [acentricresearch.com](https://acentricresearch.com/research/landscape-2026-11/#exclusions)(accessed 2026-11-18; page not yet deployed, read from the repository copy)
9. Vishnu Priya N, “EMA qualifies Unlearn’s AI-driven approach for smaller trials”, Clinical Trials Arena, 2022-09-29 (trade publication; includes company statements). [clinicaltrialsarena.com](https://www.clinicaltrialsarena.com/news/ema-qualifies-unlearn-approach/?ref=acentricresearch.com) (accessed 2026-11-18)
10. Amit Chowdhry, “Trially AI: $4.7 Million Raised For AI-Based Clinical Trial Recruitment Platform”, Pulse 2.0, 2025-09-22 (company-sourced report). [pulse2.com](https://pulse2.com/trially-ai-4-7-million-raised-for-ai-based-clinical-trial-recruitment-platform?ref=acentricresearch.com) (accessed 2026-11-18)
11. Amit Chowdhry, “Valinor Raises $13 Million To Advance AI-Driven Patient Selection For Clinical Trials”, Pulse 2.0, 2025-12-13 (company-sourced report). [pulse2.com](https://pulse2.com/valinor-13-million-seed-funding/amp/?ref=acentricresearch.com) (accessed 2026-11-18)
12. US Food and Drug Administration, “Medical Device Databases”. [fda.gov](https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/medical-device-databases?ref=acentricresearch.com) (accessed 2026-11-18)
13. Acentric Research, Landscape Report data appendix, evidence.json (records ClinicalTrials.gov: “AI use is not a coded field; would need text search”). [acentricresearch.com](https://acentricresearch.com/report-data/#landscape-report-november-2026) (accessed 2026-11-18; not yet deployed, read from the repository copy)
14. US Securities and Exchange Commission, “Search Filings” (EDGAR). [sec.gov](https://www.sec.gov/search-filings?ref=acentricresearch.com) (accessed 2026-11-18)
15. ARPA-H, “Programs”. [arpa-h.gov](https://arpa-h.gov/explore-funding/programs?ref=acentricresearch.com) (accessed 2026-11-18)
16. National Institutes of Health, “RePORTER”. [reporter.nih.gov](https://reporter.nih.gov/?ref=acentricresearch.com) (accessed 2026-11-18)
17. European Medicines Agency, “Qualification of novel methodologies for medicine development (QoNM)”. [ema.europa.eu](https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance/qualification-novel-methodologies-medicine-development-qonm?ref=acentricresearch.com) (accessed 2026-11-18)